Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffin

D J Gracie^{1

2}, A C Ford^{1

2}

Affiliations

¹ Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
² Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK.

Editorial

D J Gracie et al. Aliment Pharmacol Ther. 2017 Aug.

. 2017 Aug;46(4):461-462.

doi: 10.1111/apt.14180.

D J Gracie^{1

2}, A C Ford^{1

2}

¹ Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
² Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK.

No abstract available

Comment in

Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffin. Authors' reply.
Kruis W, Greinwald R. Kruis W, et al. Aliment Pharmacol Ther. 2017 Aug;46(4):462-463. doi: 10.1111/apt.14193. Aliment Pharmacol Ther. 2017. PMID: 28707787 Free PMC article. No abstract available.

Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence.
Kruis W, Kardalinos V, Eisenbach T, Lukas M, Vich T, Bunganic I, Pokrotnieks J, Derova J, Kondrackiene J, Safadi R, Tuculanu D, Tulassay Z, Banai J, Curtin A, Dorofeyev AE, Zakko SF, Ferreira N, Björck S, Diez Alonso MM, Mäkelä J, Talley NJ, Dilger K, Greinwald R, Mohrbacher R, Spiller R. Kruis W, et al. Aliment Pharmacol Ther. 2017 Aug;46(3):282-291. doi: 10.1111/apt.14152. Epub 2017 May 23. Aliment Pharmacol Ther. 2017. PMID: 28543263 Free PMC article. Clinical Trial.